Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy.

[1]  R. Sylvester,et al.  Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. , 2013, European urology.

[2]  J. M. Gaya,et al.  La re-resección transuretral puede no ser necesaria en todos los tumores vesicales no músculo-invasivos de alto grado , 2012 .

[3]  R. Sylvester,et al.  Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. , 2012, European urology.

[4]  Raj Persad,et al.  A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. , 2011, The Journal of urology.

[5]  G. Dalbagni,et al.  Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. , 2011, European urology.

[6]  T. H. van der Kwast,et al.  Long‐term follow‐up of T1 high‐grade bladder cancer after intravesical bacille Calmette‐Guérin treatment , 2011, BJU international.

[7]  D. Lamm,et al.  Maintenance Bacillus Calmette-Guerin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer , 2010 .

[8]  T. D. de Reijke,et al.  Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladd , 2010, European urology.

[9]  B. Bochner,et al.  Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. , 2009, European urology.

[10]  J. Witjes,et al.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. , 2009, European urology.

[11]  H. Herr.  Is maintenance Bacillus Calmette-Guérin really necessary? , 2008, European urology.

[12]  D. Lamm,et al.  Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events. , 2008 .

[13]  L. Martínez-Piñeiro,et al.  Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. , 2008, European urology.

[14]  E. Solsona,et al.  A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. , 2007, European urology.

[15]  F. Saint,et al.  The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. , 2006, The Journal of urology.

[16]  E. H. Lambert,et al.  The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy , 2007, BJU international.

[17]  L. Martínez-Piñeiro,et al.  Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. , 2005, The Journal of urology.

[18]  F. Burkhard,et al.  Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? , 2004, The Journal of urology.

[19]  D. Grignon,et al.  Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. , 2004, Urologic oncology.

[20]  A. Böhle,et al.  Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. , 2004, Urology.

[21]  B. Malavaud.  T1G3 bladder tumours: the case for radical cystectomy. , 2004, European urology.

[22]  D. Lamm,et al.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.

[23]  J. L. Sebastian,et al.  Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer , 2002, BJU international.

[24]  C. Sternberg,et al.  Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience. , 2002, Urology.

[25]  Michael Cookson,et al.  Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. , 2001, The Journal of urology.

[26]  D. Lamm,et al.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.

[27]  Michael Cookson,et al.  Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. , 1992, The Journal of urology.

[28]  J. Gschwend,et al.  An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. , 2010, European urology.

[29]  W. Otto,et al.  Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? , 2008, European urology.

[30]  D. Margel,et al.  Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy. , 2007, Urology.

[31]  L. Mazzucchelli,et al.  A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. , 2003, The Journal of urology.

[32]  A. Böhle,et al.  Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. , 2003, The Journal of urology.